Biolyst › TAKTAKEDA PHARMACEUTICAL CO LTD is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer on October 31, 2026. There are 23 upcoming events on record.
Across 272 concluded trials, 87% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Date Event Type Phase
October 31, 2026
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer Trial Milestone
Phase 1/Phase 2
March 16, 2027
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura Trial Milestone
Phase 3
September 13, 2027
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) Trial Milestone
Phase 3
September 24, 2027
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis Trial Milestone
Phase 3
December 6, 2027
A Study of TAK-755 in Adults With Acute Ischemic Stroke Trial Milestone
Phase 2
February 28, 2028
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions Trial Milestone
Phase 2/Phase 3
February 28, 2028
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis Trial Milestone
Phase 2
March 16, 2028
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia Trial Milestone
Phase 3
March 31, 2028
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India Trial Milestone
Phase 4
April 6, 2028
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) Trial Milestone
Phase 1
May 16, 2028
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Trial Milestone
Phase 3
June 25, 2028
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Trial Milestone
Phase 3
July 1, 2028
A Study of Rusfertide in Adults With Polycythemia Vera in China Trial Milestone
Phase 2
August 26, 2028
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) Trial Milestone
Phase 3
November 1, 2028
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer Trial Milestone
Phase 3
January 1, 2029
Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment Trial Milestone
Phase 2/Phase 3
January 17, 2029
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Trial Milestone
Phase 3
July 29, 2029
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia Trial Milestone
Phase 3
December 7, 2029
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Trial Milestone
Phase 3
December 18, 2029
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis Trial Milestone
Phase 3
January 31, 2030
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis Trial Milestone
Phase 3
April 18, 2030
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Trial Milestone
Phase 3
May 2, 2033
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease Trial Milestone
Phase 3
Track TAK alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open TAK in the tracker
Recent history
Date Event Type Phase
September 14, 2026
6-K filed: Foreign issuer report Filing
—
August 31, 2026
6-K filed: Foreign issuer report Filing
—
August 6, 2026
6-K filed: Foreign issuer report Filing
—
July 30, 2026
6-K filed: Foreign issuer report Filing
—
July 14, 2026
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis Trial Milestone
Phase 2
July 9, 2026
6-K filed: Foreign issuer report Filing
—
July 8, 2026
6-K filed: Foreign issuer report Filing
—
June 29, 2026
6-K filed: Foreign issuer report Filing
—
June 29, 2026
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults Trial Milestone
Phase 3
June 26, 2026
6-K filed: Foreign issuer report Filing
—
June 24, 2026
6-K filed: Foreign issuer report Filing
—
June 24, 2026
6-K filed: Foreign issuer report Filing
—
June 24, 2026
6-K filed: Foreign issuer report Filing
—
June 17, 2026
Results filed (20-F) Earnings
—
June 9, 2026
6-K filed: Foreign issuer report Filing
—
June 5, 2026
6-K filed: Foreign issuer report Filing
—
June 5, 2026
6-K filed: Foreign issuer report Filing
—
June 1, 2026
6-K filed: Foreign issuer report Filing
—
May 26, 2026
6-K filed: Foreign issuer report Filing
—
May 26, 2026
6-K filed: Foreign issuer report Filing
—
May 26, 2026
6-K filed: Foreign issuer report Filing
—
May 26, 2026
6-K filed: Foreign issuer report Filing
—
May 26, 2026
6-K filed: Foreign issuer report Filing
—
May 19, 2026
6-K filed: Foreign issuer report Filing
—
May 13, 2026
6-K filed: Foreign issuer report Filing
—
May 13, 2026
6-K filed: Foreign issuer report Filing
—
April 16, 2026
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Trial Milestone
Phase 2
March 30, 2026
6-K filed: Foreign issuer report Filing
—
March 26, 2026
6-K filed: Foreign issuer report Filing
—
March 25, 2026
6-K filed: Foreign issuer report Filing
—
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.